A proposed cervical vaccine candidate can reduce incidence of the disease by up to 80 percent, GlaxoSmithKline reported on Monday.

The projections were based on data gathered from clinical trial data, GSK said. The findings were reported at a conference in Denmark.

GSK’s proposed vaccine is currently in Phase III clinical trials. The vaccine is called Cervarix.

More than 16,000 women around the world have received the vaccine as part of clinical trials.

GSK operates one of its two U.S. headquarters in Research Triangle Park.

GSK: www.gsk.com